These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 16281308

  • 1. New pyrimido[5,4-c]cinnolines with antiplatelet activities.
    Rehse K, Gonska H.
    Arch Pharm (Weinheim); 2005 Dec; 338(12):590-7. PubMed ID: 16281308
    [Abstract] [Full Text] [Related]

  • 2. New purines with antiplatelet activity.
    Märschenz K, Rehse K.
    Arch Pharm (Weinheim); 2006 Mar; 339(3):115-22. PubMed ID: 16493596
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and antiplatelet activity of new imidazole-4-carboxylic acid derivatives.
    Rehse K, Steege J.
    Arch Pharm (Weinheim); 2005 Nov; 338(11):539-47. PubMed ID: 16281307
    [Abstract] [Full Text] [Related]

  • 4. New 1H-pyrazole-4-carboxamides with antiplatelet activity.
    Rehse K, Kotthaus J, Khadembashi L.
    Arch Pharm (Weinheim); 2009 Jan; 342(1):27-33. PubMed ID: 19051198
    [Abstract] [Full Text] [Related]

  • 5. New 2-amino-thiazole-4-acetamides with antiplatelet activity.
    Rehse K, Baselt T.
    Arch Pharm (Weinheim); 2008 Oct; 341(10):645-54. PubMed ID: 18720337
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and evaluation of antiplatelet activity of trihydroxychalcone derivatives.
    Zhao LM, Jin HS, Sun LP, Piao HR, Quan ZS.
    Bioorg Med Chem Lett; 2005 Nov 15; 15(22):5027-9. PubMed ID: 16169724
    [Abstract] [Full Text] [Related]

  • 7. Structure-activity relationship studies on chalcone derivatives: potent inhibition of platelet aggregation.
    Ko HH, Hsieh HK, Liu CT, Lin HC, Teng CM, Lin CN.
    J Pharm Pharmacol; 2004 Oct 15; 56(10):1333-7. PubMed ID: 15482650
    [Abstract] [Full Text] [Related]

  • 8. Synthesis, in vitro antiplatelet activity and molecular modelling studies of 10-substituted 2-(1-piperazinyl)pyrimido[1,2-a]benzimidazol-4(10H)-ones.
    Di Braccio M, Grossi G, Signorello MG, Leoncini G, Cichero E, Fossa P, Alfei S, Damonte G.
    Eur J Med Chem; 2013 Apr 15; 62():564-78. PubMed ID: 23425969
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and inhibitory activities on platelet aggregation of some flavonoid analogues.
    Göker H, Tunçbilek M, Leoncini G, Buzzi E, Mazzei M, Rolland Y, Ertan R.
    Arzneimittelforschung; 1995 Feb 15; 45(2):150-5. PubMed ID: 7710437
    [Abstract] [Full Text] [Related]

  • 10. Modulation of platelet and leucocyte function by a Chinese herbal formulation as compared with conventional antiplatelet agents.
    Zhao L, Gaudry L, Dunkley S, Brighton T, Guo ZX, Ye ZL, Luo RZ, Chesterman CN.
    Platelets; 2008 Feb 15; 19(1):24-31. PubMed ID: 18231935
    [Abstract] [Full Text] [Related]

  • 11. Structure-activity relationships of chalcone analogs as potential inhibitors of ADP- and collagen-induced platelet aggregation.
    Vijaya Bhaskar Reddy M, Tsai WJ, Qian K, Lee KH, Wu TS.
    Bioorg Med Chem; 2011 Dec 15; 19(24):7711-9. PubMed ID: 22055718
    [Abstract] [Full Text] [Related]

  • 12. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
    Lee JJ, Jin YR, Lim Y, Hong JT, Kim TJ, Chung JH, Yun YP.
    Vascul Pharmacol; 2006 Sep 15; 45(3):148-53. PubMed ID: 16916624
    [Abstract] [Full Text] [Related]

  • 13. Antiaggregating and antithrombotic activities of new 1, 2, 3-triazolecarboxamides.
    Cwiklicki A, Rehse K.
    Arch Pharm (Weinheim); 2004 Mar 15; 337(3):156-63. PubMed ID: 15038061
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and in vitro inhibitory activity on human platelet aggregation of novel properly substituted 4-(1-piperazinyl)coumarins.
    Di Braccio M, Grossi G, Roma G, Grazia Signorello M, Leoncini G.
    Eur J Med Chem; 2004 May 15; 39(5):397-409. PubMed ID: 15110966
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity.
    Coelho A, Raviña E, Fraiz N, Yáñez M, Laguna R, Cano E, Sotelo E.
    J Med Chem; 2007 Dec 27; 50(26):6476-84. PubMed ID: 18031002
    [Abstract] [Full Text] [Related]

  • 16. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
    Uchiyama S, Ozaki Y, Satoh K, Kondo K, Nishimaru K.
    Cerebrovasc Dis; 2007 Dec 27; 24(2-3):264-70. PubMed ID: 17622759
    [Abstract] [Full Text] [Related]

  • 17. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ, Tóth-Zsámboki E, Vargová K, László A, Masszi T, Kerecsen G, Préda I, Kiss RG.
    Thromb Haemost; 2008 Nov 27; 100(5):829-38. PubMed ID: 18989527
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity.
    Wang WY, Hsieh PW, Wu YC, Wu CC.
    Biochem Pharmacol; 2007 Aug 15; 74(4):601-11. PubMed ID: 17601492
    [Abstract] [Full Text] [Related]

  • 19. A comparative optical aggregometry study of antiplatelet activity of taxanes from Taxus cuspidata.
    Kim SY, Yun-Choi HS.
    Thromb Res; 2010 Jun 15; 125(6):e281-4. PubMed ID: 20170941
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and anti-platelet evaluation of 2-benzoylaminobenzoate analogs.
    Hsieh PW, Chiang SZ, Wu CC, Lo YC, Shih YT, Wu YC.
    Bioorg Med Chem; 2008 May 15; 16(10):5803-14. PubMed ID: 18407506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.